(Bloomberg) -- Pfizer Inc. is in advanced talks tobuy Allergan Plc for as much as $380 per share, according to peoplefamiliar with the matter, valuing the Botox maker at as high as$150 billion--if the U.S. government doesn’t get in the way of thedrug industry’s largest-ever deal.

The companies aim to announce an agreement as soon as Monday,the people said, asking not to be identified because thediscussions are private.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Employer-Paid